|
業務類別
|
Medical Devices |
|
業務概覽
|
TriSalus Life Sciences Inc is an oncology-focused medical technology business integrating its delivery technology with standard-of-care therapies and its investigational immunotherapeutic, nelitolimod, a class C Toll-like receptor 9 (TRL9)agonist, for patients with solid tumors. The company developed Pressure-Enabled Drug Delivery (PEDD) to overcome high intratumoral pressure and off-target delivery. Its 510(k) cleared device, the TriNav Infusion System using PEDD technology, is used for interventional radiology procedures including transarterial radioembolization (TARE) and transarterial chemoembolization (TACE) in patients with primary liver cancer or liver metastases. It has one reportable segment and generates revenue from sales of PEDD infusion systems, principally related to TriNav. |
| 公司地址
| 6272 W. 91st Avenue, Westminster, CO, USA, 80031 |
| 電話號碼
| +1 888 321-5212 |
| 傳真號碼
| -- |
| 公司網頁
| https://www.trisaluslifesci.com |
| 員工數量
| 102 |
| Dr. Richard Marshak, V.M.D. |
Chief Commercial Officer |
美元 435.33K |
31/03/2026 |
| Ms. Mary T. Szela |
Chief Executive Officer, President and Director |
美元 600.92K |
31/03/2026 |
| Dr. Richard Marshall, M.D. |
Medical Director |
-- |
07/04/2026 |
| Mr. David Patience |
Chief Financial Officer and Principal Accounting Officer |
美元 268.46K |
31/03/2026 |
| Ms. Jennifer Stevens |
Chief Regulatory, Quality and Therapeutics Officer |
-- |
31/03/2026 |
| Ms. Jodi Devlin |
Chief of Clinical Operations |
-- |
31/03/2026 |
| Mr. Bryan F. Cox |
Chief of Research |
-- |
31/03/2026 |
|
|
| Mr. Kerry R. Hicks |
Independent Director |
31/03/2026 |
| Mr. Mats L. Wahlstrom |
Chairman of the Board |
31/03/2026 |
| Dr. Gary Gordon |
Independent Director |
31/03/2026 |
| Ms. Mary T. Szela |
Chief Executive Officer, President and Director |
31/03/2026 |
| Mr. Michael P. Stansky |
Director |
09/02/2026 |
| Mr. David J. Matlin |
Independent Director |
31/03/2026 |
| Mr. William Valle |
Independent Director |
31/03/2026 |
|
|
|
|
